In support of this hypothesis, high MGL-binding in breast carcinoma was recently associated with the expression of HER2/neu [32], which is an upstream activator of the MAPK-cascade and has been related to an immunosuppressive tumor microenvironment [33]. This evidence concerns the gene ERBB2 and breast carcinoma.